

[Open New Account](#)

[Account Types](#)

[Funding & Transfers](#)

[Keywords or Stocks](#)

[Go](#)

[Client Login](#)



Official Sponsor

[Service](#) [Tools & Platforms](#) [Investment Products](#) [Pricing](#) [Retirement](#) [Education](#) [Research](#)

Markets: News

Markets

News

[Indices](#)

[Sectors and Industries](#)

[Calendar](#)

[Analyst Reports](#)

[Stocks](#)

[Options](#)

[Mutual Funds](#)

[ETFs](#)

[Bonds & CDs](#)

[Screeners](#)

[Ideas](#)

[Investor Movement Index \(IMX\)](#)

[At This Moment](#)

Search News

By symbol

Search

[Back to News Overview](#)

NPS Pharmaceuticals (NPSP) \$32.25 down \$0.35...

6/3/14 12:50 PM ET (S&P Capital IQ) [Print](#)

STRATEGY: Look at the July 31 covered call. For each 100 shares of NPS Pharmaceuticals (NPSP) stock you buy, sell one July 31 covered call option for a \$28.95 (\$32.25 - \$3.30) debit or better. That's potentially a 7.1% assigned return. IK -> COMMENT: The technicals for NPSP are neutral with an upward trend. The stock has support around \$22.60 and resistance near \$39.70. The company is next expected to report earnings in early August. S&P Capital IQ ranks this stock as 5 STARS (out of five) - strong buy. RISK: The stock has to drop 10.2% to threaten the break even point. This trade rates 3 keys out of 5 - moderate relative risk. S&P RESEARCH NOTES: S&P CAPITAL IQ REITERATES STRONG BUY OPINION ON SHARES OF NPS PHARMACEUTICALS. According to an unconfirmed report in the Times of London, Shire Plc (SHPG) is preparing a bid for NPSP. According to the report, SHP's initial approach to NPSP was turned down, but SHP has retained an investment banking firm and secured a \$5B credit facility to fund a deal. We think the combination makes strategic sense as both firms focus on rare diseases. In January, SHP completed the \$4.2B acquisition of specialty pharma firm ViroPharma. But we note SHP has also been subject to recent takeover rumors themselves. We keep our target price at \$42.

[Back to News Overview](#)

Latest Headlines

[Willis Tower Watson to replace Fossil Group on S&P 500](#)

12/28/2015 (MarketWatch)

[Pep Boys shares rally as Icahn increases takeover bid](#)

12/28/2015 (MarketWatch)

[Wall Street's forecast for 2016: Worse than 2015's](#)

12/28/2015 (MarketWatch)

[More recent headlines...](#)

More Options headlines

[More Options headlines...](#)

News provided by [BRIEFING.COM](#), [MarketWatch](#) Copyright ©2015. All rights reserved.

Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.

[3rd Party Research Disclosure](#) /public-19:29:42



[CLIENT LOG-IN](#)

[SECURITY](#)

[FIND A BRANCH](#)

[ABOUT US](#)

[THE TICKER TAPE](#)

[MOBILE SITE](#)

[CONTACT US](#)

[FORM LIBRARY](#)

[FEEDBACK \[-\]](#)

Stay connected with us:



DOW **17,528.27**
▼-23.9 (0.14%)

NASDAQ **5,040.99**
▼-7.5 (0.15%)

S&P 500 **2,056.5**
▼-4.49 (0.22%)

12/28/15 1:34PM PT

[Trade commission-free for 60 days plus get up to \\$600](#) Offer Details

[Open an account](#)

[Careers](#) [Search Jobs](#) [Minimum Requirements](#) [Disclosures](#) [Privacy](#) [Financial Statement](#) [Newsroom](#) [Site Map](#)

[TD Ameritrade Institutional](#) [International TDW URLs](#) [TD Ameritrade Holding Corp.](#)

[AdChoices](#)

NPS EX. 2125
CFAD v. NPS
IPR2015-00990



Find authenticated court documents without watermarks at [docketalarm.com](#).